Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™ View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-10

AUTHORS

A. N. A. Tosteson, T. P. Do, S. W. Wade, M. S. Anthony, R. W. Downs

ABSTRACT

During the first year of Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBE US), many women transitioned (i.e., discontinued or switched) from their baseline osteoporosis medication. Participants not on stable therapy at entry, with side effects, and with poor physical status were at higher risk of transitioning. Understanding factors associated with persistence may lead to improved outcomes. INTRODUCTION: Postmenopausal osteoporosis (PMO) medication use patterns may differ by treatment history and drug class. We describe these patterns among patients in primary care settings using patient-reported data. METHODS: Data from 3,006 participants of the POSSIBLE US were used to estimate the probability of a baseline PMO medication transition (i.e., discontinuation or switch) and hazard ratios (HRs) for predictors of these transitions. RESULTS: One year after study entry, the probability of persisting with a baseline medication was 66% (95% CI: 64-68%). After adjusting for age and osteoporosis diagnosis, factors at entry independently associated with a higher risk of baseline medication transition were treatment status cohort, side effect severity, and OPAQ-SV physical function score. Compared to participants stable on therapy at entry, others had a higher risk, ranging from HR = 1.59 (95% CI: 1.36-1.85) for those new to therapy to HR = 2.00 (95% CI: 1.27-3.15) for those who recently augmented therapy at entry. Participants reporting moderate (HR = 1.31, 95% CI: 1.09-1.57) or severe (HR = 1.88, 95% CI: 1.49-2.39) side effects had a higher risk than those not reporting side effects. Participants reporting Osteoporosis Assessment Questionnaire-Short Version physical function scores in the lowest tertile had a higher risk (HR = 1.27, 95% CI: 1.07-1.52) than those reporting scores in the highest tertile. CONCLUSION: Baseline osteoporosis medication transitions were common in the first year of POSSIBLE US. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions. More... »

PAGES

1769-1780

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5

DOI

http://dx.doi.org/10.1007/s00198-009-1133-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042711530

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20101492


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Substitution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Utilization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Educational Status", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epidemiologic Methods", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Dartmouth Institute for Health Policy and Clinical Practice", 
          "id": "https://www.grid.ac/institutes/grid.414049.c", 
          "name": [
            "HB 7505 Clinical Research, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA", 
            "HB 7505 Clinical Research, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tosteson", 
        "givenName": "A. N. A.", 
        "id": "sg:person.012234200657.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234200657.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, 1201 Amgen Court West, MS: WAWM 1111, 98119, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Do", 
        "givenName": "T. P.", 
        "id": "sg:person.014112272723.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014112272723.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wade", 
        "givenName": "S. W.", 
        "id": "sg:person.0617012057.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, One Amgen Center Drive, MS: 24-2-A, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anthony", 
        "givenName": "M. S.", 
        "id": "sg:person.01165514160.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165514160.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Virginia Commonwealth University", 
          "id": "https://www.grid.ac/institutes/grid.224260.0", 
          "name": [
            "Virginia Commonwealth University School of Medicine, 1101 E Marshall Street, 7-015, P.O. Box\u00a0980111, 23298-0111, Richmond, VA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Downs", 
        "givenName": "R. W.", 
        "id": "sg:person.0624451277.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624451277.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1359/jbmr.061113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000304064"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.288.3.366", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010347841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0322-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012288373", 
          "https://doi.org/10.1007/s00198-006-0322-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0322-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012288373", 
          "https://doi.org/10.1007/s00198-006-0322-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00042192-200109000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014727566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00042192-200109000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014727566"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0025-6196(11)61093-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015374342"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2008.12.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017118653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0073-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020337646", 
          "https://doi.org/10.1007/s00198-006-0073-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0073-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020337646", 
          "https://doi.org/10.1007/s00198-006-0073-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0168-8510(96)00822-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023757917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1359/jbmr.080510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031651434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9343(03)00362-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035982277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9343(03)00362-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035982277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-2-12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039428500", 
          "https://doi.org/10.1186/1477-7525-2-12"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0674-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041206509", 
          "https://doi.org/10.1007/s00198-008-0674-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0674-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041206509", 
          "https://doi.org/10.1007/s00198-008-0674-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079907x242890", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047806290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2008.12.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050858663"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0618-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051031077", 
          "https://doi.org/10.1007/s00198-008-0618-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0618-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051031077", 
          "https://doi.org/10.1007/s00198-008-0618-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4065/82.12.1493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072185771"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075109000", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.smj.0000221637.90495.66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077261117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.smj.0000221637.90495.66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077261117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.smj.0000221637.90495.66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077261117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.smj.0000221637.90495.66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077261117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083279155", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-10", 
    "datePublishedReg": "2010-10-01", 
    "description": "During the first year of Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBE US), many women transitioned (i.e., discontinued or switched) from their baseline osteoporosis medication. Participants not on stable therapy at entry, with side effects, and with poor physical status were at higher risk of transitioning. Understanding factors associated with persistence may lead to improved outcomes.\nINTRODUCTION: Postmenopausal osteoporosis (PMO) medication use patterns may differ by treatment history and drug class. We describe these patterns among patients in primary care settings using patient-reported data.\nMETHODS: Data from 3,006 participants of the POSSIBLE US were used to estimate the probability of a baseline PMO medication transition (i.e., discontinuation or switch) and hazard ratios (HRs) for predictors of these transitions.\nRESULTS: One year after study entry, the probability of persisting with a baseline medication was 66% (95% CI: 64-68%). After adjusting for age and osteoporosis diagnosis, factors at entry independently associated with a higher risk of baseline medication transition were treatment status cohort, side effect severity, and OPAQ-SV physical function score. Compared to participants stable on therapy at entry, others had a higher risk, ranging from HR = 1.59 (95% CI: 1.36-1.85) for those new to therapy to HR = 2.00 (95% CI: 1.27-3.15) for those who recently augmented therapy at entry. Participants reporting moderate (HR = 1.31, 95% CI: 1.09-1.57) or severe (HR = 1.88, 95% CI: 1.49-2.39) side effects had a higher risk than those not reporting side effects. Participants reporting Osteoporosis Assessment Questionnaire-Short Version physical function scores in the lowest tertile had a higher risk (HR = 1.27, 95% CI: 1.07-1.52) than those reporting scores in the highest tertile.\nCONCLUSION: Baseline osteoporosis medication transitions were common in the first year of POSSIBLE US. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00198-009-1133-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US\u2122", 
    "pagination": "1769-1780", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "cb73eda3273cc0daf2534883df0b158d945f5f3c472b4a30f390d4e11db0efd3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20101492"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9100105"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-009-1133-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042711530"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-009-1133-5", 
      "https://app.dimensions.ai/details/publication/pub.1042711530"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89807_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00198-009-1133-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'


 

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      59 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-009-1133-5 schema:about N0b635fb18c7b43d9a44840d3bb5effaf
2 N23ce2551e80c479aa5a13458b45fe19e
3 N3ae3123ad31d481ba07e5541fb839afa
4 N53181ba17a2f448792c63e8a6b39fbc3
5 N5e95839025104ab4a2aa575f1655aa8c
6 N64098303c3614c199b418dbd205f9d49
7 N6cc163db676f443baca5cfab865f249d
8 N914e44293ebf403989157cdbeab05b56
9 Na313f55728334dd59c792045f80c3e87
10 Na4892c360af84854b81da376ed451328
11 Nfb04ddca0e45470797d222db179cfa98
12 anzsrc-for:11
13 anzsrc-for:1117
14 schema:author N684f362e292a4db1a7426e2ee58a91ea
15 schema:citation sg:pub.10.1007/s00198-006-0073-6
16 sg:pub.10.1007/s00198-006-0322-8
17 sg:pub.10.1007/s00198-008-0618-y
18 sg:pub.10.1007/s00198-008-0674-3
19 sg:pub.10.1186/1477-7525-2-12
20 https://app.dimensions.ai/details/publication/pub.1075109000
21 https://app.dimensions.ai/details/publication/pub.1083279155
22 https://doi.org/10.1001/jama.288.3.366
23 https://doi.org/10.1016/0168-8510(96)00822-6
24 https://doi.org/10.1016/j.amjmed.2008.12.002
25 https://doi.org/10.1016/j.clinthera.2008.12.019
26 https://doi.org/10.1016/s0002-9343(03)00362-0
27 https://doi.org/10.1016/s0025-6196(11)61093-8
28 https://doi.org/10.1097/00042192-200109000-00006
29 https://doi.org/10.1097/01.smj.0000221637.90495.66
30 https://doi.org/10.1185/030079907x242890
31 https://doi.org/10.1359/jbmr.061113
32 https://doi.org/10.1359/jbmr.080510
33 https://doi.org/10.4065/82.12.1493
34 schema:datePublished 2010-10
35 schema:datePublishedReg 2010-10-01
36 schema:description During the first year of Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBE US), many women transitioned (i.e., discontinued or switched) from their baseline osteoporosis medication. Participants not on stable therapy at entry, with side effects, and with poor physical status were at higher risk of transitioning. Understanding factors associated with persistence may lead to improved outcomes. INTRODUCTION: Postmenopausal osteoporosis (PMO) medication use patterns may differ by treatment history and drug class. We describe these patterns among patients in primary care settings using patient-reported data. METHODS: Data from 3,006 participants of the POSSIBLE US were used to estimate the probability of a baseline PMO medication transition (i.e., discontinuation or switch) and hazard ratios (HRs) for predictors of these transitions. RESULTS: One year after study entry, the probability of persisting with a baseline medication was 66% (95% CI: 64-68%). After adjusting for age and osteoporosis diagnosis, factors at entry independently associated with a higher risk of baseline medication transition were treatment status cohort, side effect severity, and OPAQ-SV physical function score. Compared to participants stable on therapy at entry, others had a higher risk, ranging from HR = 1.59 (95% CI: 1.36-1.85) for those new to therapy to HR = 2.00 (95% CI: 1.27-3.15) for those who recently augmented therapy at entry. Participants reporting moderate (HR = 1.31, 95% CI: 1.09-1.57) or severe (HR = 1.88, 95% CI: 1.49-2.39) side effects had a higher risk than those not reporting side effects. Participants reporting Osteoporosis Assessment Questionnaire-Short Version physical function scores in the lowest tertile had a higher risk (HR = 1.27, 95% CI: 1.07-1.52) than those reporting scores in the highest tertile. CONCLUSION: Baseline osteoporosis medication transitions were common in the first year of POSSIBLE US. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N17e980467b3444e3907f8f55d8ef8226
41 N49357554033d498ba699b17e91070194
42 sg:journal.1100834
43 schema:name Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™
44 schema:pagination 1769-1780
45 schema:productId N3d1fab54bfb644d1a78ed47053099448
46 N9b7840bb03ba493c88952ffc7cdcf6a1
47 Na0446c17e3614888b88ec430c4cdd095
48 Nb7b103b1c0ca40ada87246267de71924
49 Nffc911234548424b93e6d978e8436e60
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042711530
51 https://doi.org/10.1007/s00198-009-1133-5
52 schema:sdDatePublished 2019-04-11T09:57
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher Nb555bc5590a847ba9fd3a7bd10a08220
55 schema:url http://link.springer.com/10.1007/s00198-009-1133-5
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N0b635fb18c7b43d9a44840d3bb5effaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Female
61 rdf:type schema:DefinedTerm
62 N17e980467b3444e3907f8f55d8ef8226 schema:volumeNumber 21
63 rdf:type schema:PublicationVolume
64 N23ce2551e80c479aa5a13458b45fe19e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Drug Substitution
66 rdf:type schema:DefinedTerm
67 N2cec5d1b1ecc4857b8c3b4f56fefb48d schema:name Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA
68 rdf:type schema:Organization
69 N3ae3123ad31d481ba07e5541fb839afa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Aged
71 rdf:type schema:DefinedTerm
72 N3d1fab54bfb644d1a78ed47053099448 schema:name pubmed_id
73 schema:value 20101492
74 rdf:type schema:PropertyValue
75 N48e05219c4b64473a0bd1a641e47535a rdf:first sg:person.0624451277.33
76 rdf:rest rdf:nil
77 N49357554033d498ba699b17e91070194 schema:issueNumber 10
78 rdf:type schema:PublicationIssue
79 N53181ba17a2f448792c63e8a6b39fbc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Treatment Outcome
81 rdf:type schema:DefinedTerm
82 N5e95839025104ab4a2aa575f1655aa8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Humans
84 rdf:type schema:DefinedTerm
85 N61d1b03db4234ea8ba79e5cb8d6d2a8e rdf:first sg:person.0617012057.00
86 rdf:rest Nc087a916a2b948d08010f64a9dfa40c2
87 N64098303c3614c199b418dbd205f9d49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Epidemiologic Methods
89 rdf:type schema:DefinedTerm
90 N684f362e292a4db1a7426e2ee58a91ea rdf:first sg:person.012234200657.45
91 rdf:rest Nf198bc1a4fe042fcb9b90c7828e6bd22
92 N6cc163db676f443baca5cfab865f249d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Drug Utilization
94 rdf:type schema:DefinedTerm
95 N914e44293ebf403989157cdbeab05b56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Middle Aged
97 rdf:type schema:DefinedTerm
98 N9b7840bb03ba493c88952ffc7cdcf6a1 schema:name dimensions_id
99 schema:value pub.1042711530
100 rdf:type schema:PropertyValue
101 Na0446c17e3614888b88ec430c4cdd095 schema:name readcube_id
102 schema:value cb73eda3273cc0daf2534883df0b158d945f5f3c472b4a30f390d4e11db0efd3
103 rdf:type schema:PropertyValue
104 Na313f55728334dd59c792045f80c3e87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Osteoporosis, Postmenopausal
106 rdf:type schema:DefinedTerm
107 Na4892c360af84854b81da376ed451328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Bone Density Conservation Agents
109 rdf:type schema:DefinedTerm
110 Nb555bc5590a847ba9fd3a7bd10a08220 schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 Nb7b103b1c0ca40ada87246267de71924 schema:name doi
113 schema:value 10.1007/s00198-009-1133-5
114 rdf:type schema:PropertyValue
115 Nc087a916a2b948d08010f64a9dfa40c2 rdf:first sg:person.01165514160.38
116 rdf:rest N48e05219c4b64473a0bd1a641e47535a
117 Nf198bc1a4fe042fcb9b90c7828e6bd22 rdf:first sg:person.014112272723.89
118 rdf:rest N61d1b03db4234ea8ba79e5cb8d6d2a8e
119 Nfb04ddca0e45470797d222db179cfa98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Educational Status
121 rdf:type schema:DefinedTerm
122 Nffc911234548424b93e6d978e8436e60 schema:name nlm_unique_id
123 schema:value 9100105
124 rdf:type schema:PropertyValue
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
129 schema:name Public Health and Health Services
130 rdf:type schema:DefinedTerm
131 sg:journal.1100834 schema:issn 0937-941X
132 1433-2965
133 schema:name Osteoporosis International
134 rdf:type schema:Periodical
135 sg:person.01165514160.38 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
136 schema:familyName Anthony
137 schema:givenName M. S.
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165514160.38
139 rdf:type schema:Person
140 sg:person.012234200657.45 schema:affiliation https://www.grid.ac/institutes/grid.414049.c
141 schema:familyName Tosteson
142 schema:givenName A. N. A.
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234200657.45
144 rdf:type schema:Person
145 sg:person.014112272723.89 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
146 schema:familyName Do
147 schema:givenName T. P.
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014112272723.89
149 rdf:type schema:Person
150 sg:person.0617012057.00 schema:affiliation N2cec5d1b1ecc4857b8c3b4f56fefb48d
151 schema:familyName Wade
152 schema:givenName S. W.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
154 rdf:type schema:Person
155 sg:person.0624451277.33 schema:affiliation https://www.grid.ac/institutes/grid.224260.0
156 schema:familyName Downs
157 schema:givenName R. W.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624451277.33
159 rdf:type schema:Person
160 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
161 https://doi.org/10.1007/s00198-006-0073-6
162 rdf:type schema:CreativeWork
163 sg:pub.10.1007/s00198-006-0322-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012288373
164 https://doi.org/10.1007/s00198-006-0322-8
165 rdf:type schema:CreativeWork
166 sg:pub.10.1007/s00198-008-0618-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1051031077
167 https://doi.org/10.1007/s00198-008-0618-y
168 rdf:type schema:CreativeWork
169 sg:pub.10.1007/s00198-008-0674-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041206509
170 https://doi.org/10.1007/s00198-008-0674-3
171 rdf:type schema:CreativeWork
172 sg:pub.10.1186/1477-7525-2-12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039428500
173 https://doi.org/10.1186/1477-7525-2-12
174 rdf:type schema:CreativeWork
175 https://app.dimensions.ai/details/publication/pub.1075109000 schema:CreativeWork
176 https://app.dimensions.ai/details/publication/pub.1083279155 schema:CreativeWork
177 https://doi.org/10.1001/jama.288.3.366 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010347841
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/0168-8510(96)00822-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023757917
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.amjmed.2008.12.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050858663
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.clinthera.2008.12.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017118653
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/s0002-9343(03)00362-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035982277
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s0025-6196(11)61093-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015374342
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1097/00042192-200109000-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014727566
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1097/01.smj.0000221637.90495.66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077261117
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1185/030079907x242890 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047806290
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1359/jbmr.061113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000304064
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1359/jbmr.080510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031651434
198 rdf:type schema:CreativeWork
199 https://doi.org/10.4065/82.12.1493 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072185771
200 rdf:type schema:CreativeWork
201 https://www.grid.ac/institutes/grid.224260.0 schema:alternateName Virginia Commonwealth University
202 schema:name Virginia Commonwealth University School of Medicine, 1101 E Marshall Street, 7-015, P.O. Box 980111, 23298-0111, Richmond, VA, USA
203 rdf:type schema:Organization
204 https://www.grid.ac/institutes/grid.414049.c schema:alternateName Dartmouth Institute for Health Policy and Clinical Practice
205 schema:name HB 7505 Clinical Research, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA
206 HB 7505 Clinical Research, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
209 schema:name Amgen Inc, 1201 Amgen Court West, MS: WAWM 1111, 98119, Seattle, WA, USA
210 Amgen Inc, One Amgen Center Drive, MS: 24-2-A, 91320, Thousand Oaks, CA, USA
211 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...